RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF
    1.
    发明申请
    RADIOACTIVE MIXTURE AND MANUFACTURING METHOD THEREOF 有权
    放射性混合物及其制造方法

    公开(公告)号:US20100183508A1

    公开(公告)日:2010-07-22

    申请号:US12354815

    申请日:2009-01-16

    IPC分类号: A61K51/04 A61P35/00

    CPC分类号: A61K51/0478 A61K49/0438

    摘要: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4−/or ReO4−, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4−/or ReO4− avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.

    摘要翻译: 公开了放射性混合物及其制造方法。 通过胺胺 - 二硫化胺胺二齿螯合配体的MN系列化合物与TcO4-或ReO4-螯合反应形成放射性混合物(188Re-MN / Lipiodol混合物),然后溶解于Lipiodol中。 此外,TcO4- /或ReO4的99mTc /或188Re避免了由自由90Y引起的骨髓损伤。 通过长时间停留在肝肿瘤中的碘碘醇的特征,通过注射施用放射性混合物来治疗肝癌,从而可以预防外科手术引起的损伤。 188Re-MN / Lipiodol用于肝癌,乳腺癌或其他实体瘤治疗。 Re-188 MN或Re-188 MN / Lipiodol可与抗癌药物,水凝胶,脂质体,胶束或其他纳米颗粒混合,形成多功能治疗方式。

    Process of Evaluating Blood-Brain Barrier Permeability of Stroke Rat by Using Fluorescent Substance
    4.
    发明申请
    Process of Evaluating Blood-Brain Barrier Permeability of Stroke Rat by Using Fluorescent Substance 有权
    使用荧光物质评估脑卒中大鼠血脑屏障通透性的过程

    公开(公告)号:US20140017173A1

    公开(公告)日:2014-01-16

    申请号:US13545238

    申请日:2012-07-10

    IPC分类号: A61K49/00

    CPC分类号: A61K49/0017 A61B5/0071

    摘要: A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized.

    摘要翻译: 公开了一种通过使用荧光物质评价中风大鼠的血脑屏障通透性的方法。 该方法使用具有自发荧光性质的伊文思蓝染料,结合使用新的非侵入性体内成像系统(IVIS)获得荧光信号,以评估啮齿动物血脑屏障通透性的变化 大脑动脉中风模型手术后。 在运行中,将伊文思蓝染料注射到大脑中动脉闭塞模型的中风大鼠中。 使用非侵入性体内成像系统检测全脑的荧光分布,并获得由整个脑组织的荧光图像和光学图像组合的图像。 由此能够完全实现卒中大鼠的血脑屏障通透性的变化。

    Process of evaluating blood-brain barrier permeability of stroke rat by using fluorescent substance
    6.
    发明授权
    Process of evaluating blood-brain barrier permeability of stroke rat by using fluorescent substance 有权
    使用荧光物质评估卒中大鼠血脑屏障通透性的过程

    公开(公告)号:US09017646B2

    公开(公告)日:2015-04-28

    申请号:US13545238

    申请日:2012-07-10

    IPC分类号: A61K49/00 A61B5/00

    CPC分类号: A61K49/0017 A61B5/0071

    摘要: A process of evaluating blood-brain barrier permeability of a stroke rat by using fluorescent substance is disclosed. This process uses an Evans blue dye having spontaneous fluorescence properties, in combination with the use of a new non-invasive in vivo imaging system (IVIS), to obtain fluorescent signals so as to assess the change in the blood-brain barrier permeability of rodents after a cerebral artery stroke model surgery. In operation, an Evans blue dye is injected into a stroke rat of middle cerebral artery occlusion model. A non-invasive in vivo imaging system is used to detect the fluorescence distribution of the whole brain, and obtain images combined by the fluorescence images and optical images for the whole brain tissue. Thereby, the change in the blood-brain barrier permeability of the stroke rat can be completely realized.

    摘要翻译: 公开了一种通过使用荧光物质评价中风大鼠的血脑屏障通透性的方法。 该方法使用具有自发荧光性质的伊文思蓝染料,结合使用新的非侵入性体内成像系统(IVIS)获得荧光信号,以评估啮齿动物血脑屏障通透性的变化 大脑动脉中风模型手术后。 在运行中,将伊文思蓝染料注射到大脑中动脉闭塞模型的中风大鼠中。 使用非侵入性体内成像系统检测全脑的荧光分布,并获得由整个脑组织的荧光图像和光学图像组合的图像。 由此能够完全实现卒中大鼠的血脑屏障通透性的变化。

    METHOD OF MAKING A GRINDING DISK AND A GRINDING DISK
    7.
    发明申请
    METHOD OF MAKING A GRINDING DISK AND A GRINDING DISK 有权
    研磨盘和研磨盘的制造方法

    公开(公告)号:US20120231712A1

    公开(公告)日:2012-09-13

    申请号:US13509340

    申请日:2010-12-20

    IPC分类号: B24D5/16 B24D18/00

    摘要: The invention relates to a method of making a grinding disk, comprising the steps of: providing a cap; providing an abrasive part; placing the cap on the abrasive part to form an assembly; holding the assembly and injecting a molding material into a space between the cap and the abrasive part and into the abrasive part to bond the cap and the abrasive part. A grinding disk made by the method is also disclosed.

    摘要翻译: 本发明涉及一种制造研磨盘的方法,包括以下步骤:提供盖; 提供研磨部分; 将盖放置在磨料部分上以形成组件; 保持组件并将模制材料注入到盖和研磨部分之间的空间中并进入研磨部分以将盖和研磨部分结合。 还公开了通过该方法制造的研磨盘。

    Radioactive mixture and manufacturing method thereof
    8.
    发明授权
    Radioactive mixture and manufacturing method thereof 有权
    放射性混合物及其制造方法

    公开(公告)号:US08048405B2

    公开(公告)日:2011-11-01

    申请号:US12354815

    申请日:2009-01-16

    IPC分类号: A61K49/00

    CPC分类号: A61K51/0478 A61K49/0438

    摘要: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4−/or ReO4−, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4−/or ReO4− avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.

    摘要翻译: 公开了放射性混合物及其制造方法。 通过胺胺 - 二硫化胺胺二齿螯合配体的MN系列化合物与TcO4-或ReO4-螯合反应形成放射性混合物(188Re-MN / Lipiodol混合物),然后溶于Lipiodol中。 此外,TcO4- /或ReO4的99mTc /或188Re避免了由自由90Y引起的骨髓损伤。 通过长时间停留在肝肿瘤中的碘碘醇的特征,通过注射施用放射性混合物来治疗肝癌,从而可以预防外科手术引起的损伤。 188Re-MN / Lipiodol用于肝癌,乳腺癌或其他实体瘤治疗。 Re-188 MN或Re-188 MN / Lipiodol可与抗癌药物,水凝胶,脂质体,胶束或其他纳米颗粒混合,形成多功能治疗方式。

    Radioactive material for inhibiting cancer and preparation method thereof
    9.
    发明申请
    Radioactive material for inhibiting cancer and preparation method thereof 审中-公开
    用于抑制癌症的放射性物质及其制备方法

    公开(公告)号:US20090324496A1

    公开(公告)日:2009-12-31

    申请号:US12147733

    申请日:2008-06-27

    IPC分类号: A61K51/00 A61P35/00

    CPC分类号: A61K51/1051 A61K51/1093

    摘要: A radioactive material for inhibiting cancer and a preparation method thereof are disclosed. The radioactive material for inhibiting cancer is M-SOCTA-Z and M is a radioactive nuclide such as 188Re or 99mT while Z is protein or peptides having amino acid with NH or NH2 group. The preparation method of the radioactive material for inhibiting cancer includes steps of: reacting SOCTA with protein or peptide. Ester (—COOR) in SOCTA reacts with amines (—NH, —NH2) in protein or peptide to form peptide bond. Thus SOCTA-protein or SOCTA-peptide complex is produced. Then these SOCTA-protein complex reacts with radioactive nuclide M so as to generate M-SOCTA-protein or M-SOCTA-peptide. In an embodiment of the present invention, monoclonal antibody Herceptin is applied to bind with SOCTA and in combination with radiation-based therapy, effects of cancer treatment (such as breast cancer) are enhanced.

    摘要翻译: 公开了一种抑制癌症的放射性物质及其制备方法。 用于抑制癌症的放射性物质是M-SOCTA-Z,M是188Re或99mT的放射性核素,而Z是具有氨基酸与NH或NH 2基团的蛋白质或肽。 用于抑制癌症的放射性物质的制备方法包括以下步骤:使SOCTA与蛋白质或肽反应。 SOCTA中的酯(-COOR)与蛋白质或肽中的胺(-NH,-NH2)反应形成肽键。 因此产生SOCTA蛋白或SOCTA-肽复合物。 然后这些SOCTA-蛋白质复合物与放射性核素M反应,产生M-SOCTA-蛋白或M-SOCTA-肽。 在本发明的一个实施方案中,应用单克隆抗体赫赛汀与SOCTA结合,并结合放射治疗,增强了癌症治疗(如乳腺癌)的效果。